ClinicalTrials.gg
CompletedNCT01449058Updated Oct 2, 2017

A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors

A Phase 1 interventional study of BYL719 and MEK162 in Advanced and Selected Solid Tumors, AML and High Risk and Very High Risk MDS, sponsored by Array BioPharma. Completed at 16 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-10-02.

Sponsored by Array BioPharma (part of Pfizer) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
139
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is a multi-center, open-label, dose-finding, phase Ib study to estimate the maximum tolerated dose(s) (MTD(s)) and/or recommended dose(s) for expansion (RDE(s)) for the orally administered combination of BYL719 and MEK162. This combination will be explored in adult patients with advanced CRC, esophageal cancer, pancreatic cancer, NSCLC, ovarian cancer, or other advanced solid tumors and in adult patients with AML or high risk and very high risk MDS, with documented RAS or BRAF mutations. Dose escalation will be guided by a Bayesian logistic regression model with overdose control. At MTD or RDE, four expansion arms will be opened in order to further assess the safety and preliminary activity of the combination of BYL719 and MEK162 in specific patient populations.

02

Conditions studied

  • Advanced and Selected Solid Tumors
  • AML
  • High Risk and Very High Risk MDS

Keywords

  • Advanced solid tumor,
  • AML
  • high risk and very high risk MDS
  • dose escalation,
  • RAS/BRAF mutation,
  • PI3K inhibitor,
  • MEK inhibitor,
  • BYL719,
  • MEK162
03

In context

Lead sponsor

Array BioPharma is the lead sponsor of 6 studies on the registry; none are open to participants now.

First submitted before Array Biopharma became part of Pfizer.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histologically/ confirmed, advanced solid tumors, AML or high risk and very high risk MDS
  • as determined by 1.1

Exclusion criteria

Exclusion Criteria:

  • Primary CNS tumor or CNS tumor involvement
  • Diabetes mellitus
  • Unacceptable ocular/retinal conditions
  • cardiac disease or impaired cardiac function
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
139 participants (actual)

Study arms

  • Experimental
    BYL719 + MEK162

    BYL719 plus MEK162. Dose escalation with a starting dose for the first cohort of 200mg QD BYL719 and 30mg BID MEK162

    Drug: BYL719 · Drug: MEK162

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of Dose Limiting Toxicities (DLT)

    Toxicity will be assessed using the National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE), version 4.0 unless otherwise specified. A DLT is defined as an adverse event or abnormal laboratory value assessed as at least possibly related to the study medication, occurs ≤ 28 days following the first dose of BYL719 and MEK162 (Cycle 1), and meets any of the protocol-specified DLT criteria.

    Time frame: during the first cycle (28 days) of treatment with BYL719 and MEK162

Secondary outcomes

  1. Number of participants with adverse events and serious adverse events

    All AEs and SAEs will be collected in accordance with the protocol and assessed for relatedness to study drug combination.

    Time frame: Assessed from Cycle 1 Day 1 until treatment discontinuation

  2. Overall response rate

    Overall response rate (ORR) is the proportion of patients with a best overall response of Complete Response (CR) or Partial Response (PR).

    Time frame: Assessed every 8 weeks until disease progression

  3. Time to progression

    Time to progression (TTP) is the time from date of randomization/start of treatment to the date of event defined as the first documented progression or death due to underlying cancer. If a patient has not had an event, time to progression is censored at the date of last adequate tumor assessment.

    Time frame: Assessed every 8 weeks until disease progression

  4. Progression free survival

    Progression-free survival (PFS) is the time from date of randomization/start of treatment to the date of event defined as the first documented progression or death due to any cause. If a patient has not had an event, progression-free survival is censored at the date of last adequate tumor assessment.

    Time frame: Assessed every 8 weeks until disease progression

  5. Time versus plasma concentration profiles of BYL719 and MEK162

    Blood concentrations of MEK162 and its metabolite (AR00426032) and BYL719 will be assessed during the first cycle of treatment.

    Time frame: Assessed during the first cycle of treatment

  6. Correlation of baseline mutation or amplification status (PIK3CA, KRAS, NRAS and BRAF) and clinical anti-tumor activity outcome

    Collect baseline genetic mutation/alteration status to investigate the potential relationship to anti-tumor activity.

    Time frame: Assessed at Baseline (pre-treatment)

  7. Clinical benefit rate

    The clinical benefit rate is defined as the proportion of patients with complete remission, complete remission with incomplete blood count recovery, partial remission, minor response or stable disease for \> 15 weeks

    Time frame: Assessed every 4 weeks for 3 months and every 3 months for 6 months followed by every 6 months thereafter until disease progression

07

Study locations

16 sites
  • University of California San Diego - Moores Cancer Center Dept Onc
    La Jolla, California 92093-0658, United States
  • H. Lee Moffitt Cancer Center & Research Institute H. Lee Moffitt SC
    Tampa, Florida 33612, United States
  • Northwestern Memorial Hospital
    Chicago, Illinois 60611, United States
  • Massachusetts General Hospital CCPO
    Boston, Massachusetts 02114, United States
  • Memorial Sloan Kettering Cancer Center Onc. Dept
    New York, New York 90033, United States
  • Montefiore Medical Center SC
    The Bronx, New York 10461, United States
  • University of Texas/MD Anderson Cancer Center Dept. of Onc.
    Houston, Texas 77030-4009, United States
  • University of Utah / Huntsman Cancer Institute Huntsman (3)
    Salt Lake City, Utah 84103, United States
  • Array BioPharma Investigative Site
    Parkville, Victoria 3050, Australia
  • Array BioPharma Investigative Site
    Villejuif Cedex, 94805, France
  • Array BioPharma Investigative Site
    Milano, MI 20133, Italy
  • Array BioPharma Investigative Site
    Roma, RM 00168, Italy
  • Array BioPharma Investigative Site
    Barcelona, Catalunya 08035, Spain
  • Array BioPharma Investigative Site
    Barcelona, Catalunya 08036, Spain
  • Array BioPharma Investigative Site
    Bellinzona, 6500, Switzerland
  • Array BioPharma Investigative Site
    Sutton, SM2 5PT, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2012, a primary completion of Aug 2016 and a completion of Aug 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2011
First posted
Oct 7, 2011
Start
Mar 2012
Primary completionActual
Aug 31, 2016
CompletionActual
Aug 15, 2017
Last update
Oct 2, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 2, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01449058
Lead sponsor
Array BioPharma
Responsible party
Sponsor
First posted
Oct 7, 2011
Start date
Mar 2012
Primary completion
Aug 31, 2016
Completion
Aug 15, 2017
Last update
Oct 2, 2017

Study contacts

Array BioPharma
study director · 303-381-6604
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Alpelisib · Binimetinib

Start the discussion